Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lux Capital
BioCentury | Feb 20, 2025
Finance
Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report
Plus fundings around the globe for Eg 427, Atrandi and Reverb
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Jan 10, 2025
Finance
Life science VCs driving AI innovation: the view from the interface in 2025
How VC firms focused on AI-driven drug development think about the resources and strategies needed to turn promise into reality
BioCentury | Dec 20, 2024
Management Tracks
New business, medical and technology heads at Neutrolis
Plus: Noema hires Volker Knappertz as EVP of R&D, and updates from Lux, COA, Imbed and March Bio
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Sep 5, 2024
Finance
Venture Report: Megarounds for ArsenalBio, eGenesis
Developers of programmable CAR T therapies and human-compatible organs for transplantation garner nine-figure fundings
BioCentury | Jun 28, 2024
Finance
Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne
Plus: New fundings for Exsilio, TwoStep and Augustine
BioCentury | May 7, 2024
Emerging Company Profile
Xaira’s $1B AI play: de novo antibodies now, causal biology to follow
Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
BioCentury | Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
Items per page:
1 - 10 of 114